Skip to main navigation Skip to search Skip to main content

UB CAT: Development of novel therapeutic IpY for ER/PR+ HER2- breast cancer: Commercialization and in-house validation of the peptide drug substance

Project: Research

Project Details

StatusFinished
Effective start/end date08/1/22 → 06/30/23

Funding

  • Concarlo Holdings LLC: $123,888.00